Upfront tandem autologous non‐myeloablative allogeneic stem cell transplant in high‐risk multiple myeloma: a long‐term single‐centre experience

The role of upfront non‐myeloablative allogeneic stem cell transplantation (NMA alloSCT) in high‐risk multiple myeloma (HR‐MM) is unclear. We evaluated outcomes of NMA alloSCT following autologous stem cell transplant (ASCT) compared with ASCT alone for newly diagnosed HR‐MM. Two‐year progression‐fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Phillip C., Muirhead, Jenny, Tan, Joanne, Kalff, Anna, Bergin, Krystal, Walker, Patricia, Spencer, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543527/
https://www.ncbi.nlm.nih.gov/pubmed/35808923
http://dx.doi.org/10.1111/imj.15842
Descripción
Sumario:The role of upfront non‐myeloablative allogeneic stem cell transplantation (NMA alloSCT) in high‐risk multiple myeloma (HR‐MM) is unclear. We evaluated outcomes of NMA alloSCT following autologous stem cell transplant (ASCT) compared with ASCT alone for newly diagnosed HR‐MM. Two‐year progression‐free survival was improved in the ASCT‐NMA alloSCT group (44% vs 16%; P = 0.035), with a trend for improved overall survival (P = 0.118). These results suggest that ASCT‐NMA alloSCT can be considered as upfront therapy in HR‐MM.

Ejemplares similares